Side-by-side · Research reference

AHK-CuvsChonluten

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

AAnimal-MechanisticHUMAN-REVIEWED14/43 cited

BAnimal-MechanisticHUMAN-REVIEWED8/38 cited

AHK-Cu

Tripeptide-Copper Complex · Cosmetic

10⁻¹² – 10⁻⁹ MActive range (in vitro)Pyo 2007

Dermal papilla cellsPrimary targetPyo 2007

TopicalRoute

Topical · Scalp / Skin

Chonluten

Khavinson Bioregulator · Bronchial Mucosa

BronchialTarget tissue

In vitroEvidence tierAvolio 2022

THP-1Model systemAvolio 2022

Oral · Sublingual · Per Protocol

01Mechanism of Action

Parameter

AHK-Cu

Chonluten

Primary target

Dermal papilla cells (DPCs) — specialized fibroblasts in hair follicle morphogenesisPyo 2007

Bronchial epithelial cells and respiratory mucosa tissue complexes

Pathway

AHK-Cu → DPC proliferation → VEGF elevation, TGF-β1 suppression → Angiogenesis, follicle elongationPyo 2007

Bioregulatory peptide interaction → modulation of proliferative and inflammatory pathways in monocyte/macrophage populationsAvolio 2022

Downstream effect

Stimulates hair follicle elongation ex vivo, reduces dermal papilla cell apoptosis, elevates Bcl-2/Bax ratio, reduces cleaved caspase-3 and PARPPyo 2007

Regulation of proliferative activity and inflammatory mediator production in respiratory-associated immune cellsAvolio 2022

Feedback intact?

—

Origin

Synthetic tripeptide with Cu²⁺ chelation — alanine substitution variant of GHK-Cu

Khavinson bioregulator peptide complex derived from bronchial mucosa tissue extract methodology

Antibody development

—

02Dosage Protocols

Parameter

AHK-Cu

Chonluten

Effective concentration (in vitro)

10⁻¹² – 10⁻⁹ MPyo 2007

Stimulated human hair follicle elongation ex vivo and DPC proliferation in vitro.

—

Topical formulation

0.001–0.01% (estimated cosmetic range)

No standardized human protocol published — extrapolated from in vitro data.

—

Frequency

Once or twice daily (topical application)

Once or twice daily

Route

Topical — scalp or dermal application

Oral (capsule) or sublingual

Sublingual claimed for enhanced bioavailability; not validated.

Evidence basis

Ex vivo hair follicle / in vitro DPC studiesPyo 2007

In vitro mechanistic

Duration

Not established — cosmetic protocols typically 8–12 weeks

10–30 days per cycle

Traditional Khavinson protocol; cyclic administration common.

Typical protocol dose

—

10–20 mg / day

Russian bioregulator tradition dosing; not standardized in Western literature.

Clinical validation

—

None (PubMed indexed)

04Side Effects & Safety

Parameter

AHK-Cu

Chonluten

Local irritation

Mild erythema, pruritus at application site (copper peptide class effect)

—

Copper sensitivity

Rare hypersensitivity reaction in copper-sensitive individuals

—

Systemic absorption

Minimal via topical route — systemic copper toxicity unlikely at cosmetic doses

—

Data limitations

No published human safety trials — cosmetic use presumed safe per class precedent (GHK-Cu)

—

Documented adverse events

—

No published safety data in PubMed-indexed literature

Theoretical risks

—

Peptide hypersensitivity, GI intolerance (uncharacterized)

Drug interactions

—

Unknown — no pharmacokinetic studies available

Pregnancy / lactation

—

No data — avoid

Absolute Contraindications

AHK-Cu

·Known copper allergy or Wilson's disease

Chonluten

·Known hypersensitivity to peptide components

Relative Contraindications

AHK-Cu

·Broken or inflamed skin (increased absorption risk)
·Concurrent use of other copper-containing formulations

Chonluten

·Pregnancy and lactation (insufficient data)
·Active malignancy (theoretical bioregulator concern)

05Administration Protocol

Parameter

AHK-Cu

Chonluten

1. Topical application

Apply to clean, dry scalp or target dermal area. Typical cosmetic formulations: 0.001–0.01% AHK-Cu in serum or cream base.

Typically supplied as capsules or sublingual tablets. No reconstitution required. Store in cool, dry place away from light.

2. Frequency

Once or twice daily. Evening application preferred for overnight contact time.

Swallow capsule with water, 20–30 minutes before meals or as directed. Traditional Khavinson protocol emphasizes empty stomach for absorption.

3. Scalp preparation

For hair growth: apply directly to scalp, massage gently. No need to rinse. Allow absorption for minimum 2–4 hours.

Place tablet under tongue, allow dissolution for 1–2 minutes. Avoid swallowing immediately. Claimed to bypass first-pass metabolism.

4. Storage

Room temperature, protected from light. Copper complexes may degrade in UV exposure.

Morning dose preferred; may split into twice-daily if higher dose used. Consistency emphasized in bioregulator protocols.

5. Duration

Minimum 8–12 weeks to assess efficacy in hair growth applications, per typical cosmetic peptide protocols.

10–30 day cycles common in Russian tradition. Rest period of 1–3 months between cycles often recommended, though no published evidence for this approach.

06Stack Synergy

AHK-Cu

+ GHK-Cu

Moderate

View GHK-Cu →

Both tripeptide-copper complexes share overlapping angiogenic and wound-healing mechanisms (VEGF elevation, TGF-β modulation, fibroblast proliferation). AHK-Cu's alanine substitution may offer distinct receptor affinity or pharmacokinetics. Co-formulation could provide complementary dermal signaling, though no direct synergy studies exist. Often used interchangeably or in alternating protocols.

AHK-Cu: 0.001–0.01% topical · AM
GHK-Cu: 0.001–0.01% topical · PM
Frequency: Daily alternation or combined formulation
Primary benefit: Comprehensive dermal regeneration, angiogenesis, hair follicle support

Chonluten

— no documented stacks